Epidermal Growth Factor Receptor: Is It a Feasible Target for the Treatment of Osteosarcoma?.
- Author:
Jun Ah LEE
1
;
Yunmi KO
;
Dong Ho KIM
;
Jung Sub LIM
;
Chang Bae KONG
;
Wan Hyeong CHO
;
Dae Geun JEON
;
Soo Yong LEE
;
Jae Soo KOH
Author Information
1. Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.
- Publication Type:In Vitro ; Original Article
- Keywords:
Epidermal growth factor receptor;
Osteosarcoma;
Treatment
- MeSH:
Biopsy;
Blotting, Western;
Cell Line;
Cell Survival;
Codon;
Epidermal Growth Factor;
Exons;
Gene Expression;
Humans;
Immunohistochemistry;
Osteoblasts;
Osteosarcoma;
Protein-Tyrosine Kinases;
Quinazolines;
Receptor, Epidermal Growth Factor;
Retrospective Studies;
Sequence Analysis, DNA;
Tetrazolium Salts;
Thiazoles
- From:Cancer Research and Treatment
2012;44(3):202-209
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Features of epidermal growth factor receptor (EGFR) expression in osteosarcoma and in vitro efficacies of EGFR inhibitors against osteosarcoma cells were evaluated. MATERIALS AND METHODS: Thirty biopsy samples of osteosarcoma patients were retrospectively analyzed for EGFR protein expression by immunohistochemistry. Relationships between EGFR expression and clinicopathologic characteristics and treatment outcomes were evaluated. Four osteosarcoma cell lines were analyzed for EGFR and p-EGFR expression by western blotting. Efficacies of gefitinib and BIBW2992 on osteosarcoma cells were evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Tyrosine kinase domains in exons 18 to 21 were sequenced and gene expression analyses of EGFR and PTEN were performed in four osteosarcoma cell lines. RESULTS: EGFR protein was expressed in 27 (90%) samples (6 low, 12 intermediate, 9 high) and in three cell lines. Intermediate or high staining for EGFR was related to a tumor volume<150 mL (p<0.001) and histologic subtype other than osteoblastic type (p=0.03). However, EGFR expression was not associated with histologic response to preoperative chemotherapy or survival. Gefitinib and BIBW 2992 did not have any significant inhibitory effect on cell viabilities. DNA sequencing analysis revealed three osteosarcoma cell lines have single base changes at codon 2361 of exon 20 (G to A), without affecting translation results. Furthermore, no mutation was found to be associated with constitutive EGFR activation. CONCLUSION: In the present study, gefitinib and BIBW2992 were not effective against osteosarcoma cells. However, as osteosarcoma cells express EGFR, further studies are necessary to explore the potential of other therapeutic agents targeting EGFR.
